Shares of PRA Health Sciences (NASDAQ:PRAH) have been given an average recommendation of “Buy” by the thirteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, ten have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $95.18.
A number of analysts recently weighed in on PRAH shares. BidaskClub raised shares of PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, December 27th. Barclays started coverage on shares of PRA Health Sciences in a research note on Monday, December 11th. They issued an “overweight” rating and a $94.00 price objective for the company. Zacks Investment Research lowered shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, January 18th. Mizuho lowered shares of PRA Health Sciences from a “buy” rating to a “neutral” rating and set a $86.00 price objective for the company. in a research note on Wednesday, January 24th. Finally, KeyCorp reissued a “buy” rating and set a $100.00 price target on shares of PRA Health Sciences in a research report on Wednesday, January 31st.
PRAH stock traded down $1.00 during trading hours on Friday, reaching $88.45. 114,474 shares of the company were exchanged, compared to its average volume of 435,078. PRA Health Sciences has a 52 week low of $58.24 and a 52 week high of $95.90. The stock has a market capitalization of $5,727.79, a price-to-earnings ratio of 67.92, a PEG ratio of 1.41 and a beta of 0.46. The company has a current ratio of 0.90, a quick ratio of 0.90 and a debt-to-equity ratio of 1.31.
PRA Health Sciences (NASDAQ:PRAH) last released its quarterly earnings data on Wednesday, February 21st. The medical research company reported $1.04 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.02 by $0.02. PRA Health Sciences had a net margin of 3.85% and a return on equity of 22.77%. The company had revenue of $568.80 million during the quarter, compared to analyst estimates of $543.78 million. During the same period in the prior year, the firm earned $0.71 earnings per share. The firm’s revenue for the quarter was up 37.5% compared to the same quarter last year. sell-side analysts predict that PRA Health Sciences will post 3.81 EPS for the current fiscal year.
In related news, insider David W. Dockhorn sold 72,850 shares of the stock in a transaction that occurred on Thursday, December 28th. The shares were sold at an average price of $90.83, for a total value of $6,616,965.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Linda Baddour sold 67,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $90.27, for a total transaction of $6,048,090.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 212,700 shares of company stock valued at $19,282,021. Insiders own 2.10% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. IFP Advisors Inc raised its position in shares of PRA Health Sciences by 19,083.3% in the 4th quarter. IFP Advisors Inc now owns 1,151 shares of the medical research company’s stock valued at $105,000 after purchasing an additional 1,145 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. raised its position in shares of PRA Health Sciences by 52.5% in the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,647 shares of the medical research company’s stock valued at $150,000 after purchasing an additional 567 shares during the last quarter. Intrust Bank NA purchased a new position in shares of PRA Health Sciences in the 4th quarter valued at approximately $204,000. Stone Ridge Asset Management LLC purchased a new position in shares of PRA Health Sciences in the 4th quarter valued at approximately $211,000. Finally, Comerica Bank purchased a new position in shares of PRA Health Sciences in the 3rd quarter valued at approximately $214,000. 99.22% of the stock is owned by hedge funds and other institutional investors.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.